Jodi Devlin

TriSalus Life Sciences, Inc. reported in an 8-K filed April 29, 2026 that Jodi Devlin retired as Chief of Clinical Operations, effective October 1, 2026. TriSalus Life Sciences, Inc. reported in an 8-K filed January 8, 2025 that Jodi Devlin was appointed Chief of Clinical Operations, effective January 6, 2025. The proxy statement of TriSalus Life Sciences, Inc. reports total compensation of $1,383,741 for Jodi Devlin in fiscal 2024, including a base salary of $501,705. Disclosed compensation is on record for 2 fiscal years. TriSalus Life Sciences, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at TriSalus Life Sciences, Inc. includes Mary Szela (CEO and Board Member), Karim Karti (Chairman), Mats Wahlström (Chairman and Board Member) and 7 others.